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Introduction
For many years liver transplantation has been the preferred treatment for 
patients with end stage liver diseases, metabolic diseases with their primary 
defect in the liver and for patients with irresectable tumors of the liver. 
Although performed for the first time in the early sixties it took till 1983 before 
liver transplantation was accepted as a non-experimental clinical option during 
the National Institute Health consensus development conference in Washington 
USA1. At that time perioperative mortality (within one month) was 20-40%. 
This figure was considered acceptable in view of the imminent death of these 
patients. Over the years patient and graft survival have improved considerably 
as can be observed in Figure 1 from the European liver registry (ELTR)2.
 
Figure 1    Patient survival according to year of transplantation
(ELTR results: data analysis 05/1968-2000)
This improvement is likely to be due to a number of factors: surgical experience 
gained over time, increased knowledge and experience in intensive care 
medicine and more effective immunosuppression. The majority of patients and 
grafts are lost in the first months after liver transplantation. After this initial 
period patient and graft survival curves approximate survival curves of the 
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age-related general population. As a consequence attempts to improve survival, 
should be focused on the early phase following liver transplantation. 
Complications potentially leading to early patient or graft loss can be classified 
into four main groups (Table 1). In this table a number of complications are listed 
according to reports in the literature and compared to the incidence in our 
transplant center in Groningen before the start of the studies presented in this 
thesis. The first group of patients suffers from graft loss due to vascular 
problems such as hepatic artery thrombosis, portal vein thrombosis or venous 
outflow obstruction. Patients having these vascular complications often 
need either early revision of the anastomosis and thrombectomy or a 
retransplantation in order to survive.
Table 1    Complications after liver transplantation as reported in the literature 
(ranges are given) and the percentage of these complications in our center.
(ELTR results: data analysis 05/1968-2000)
A second cause of graft loss is immunological such as early therapy resistant 
acute rejection, which may lead to destruction of the graft. 
Ongoing improvement in immunosuppression will reduce the number of grafts 
lost from acute rejection. A substantial number of patients die with a well
Introduction and outline of the thesis
Groups of complications Percentage of LTx patients Percentage of LTx patients
   (literature) (Groningen 1989-1994 n=125)
Vascular thrombosis
 Hepatic artery 2 - 12 3 7
 Portal vein  1 - 14 4, 5 2
 Hepatic vein  1 - 2 6 -
Acute rejection 20 - 70 7 56
Non liver related
 Bacterial infection 50 - 70 8-10 60
 Neurological  12 - 20 11, 12 8
 Cardiac  1 - 23 13, 14 2
 Pulmonary  15 - 75 15 22
 Renal  10 - 90 16, 17 7
 Multiple organ failure 1 - 5 18, 19 5
Primary non function 2 - 10 19-21 5
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functioning graft. The causes of graft and patient losses in these patients vary 
from infection with organ failure to bleeding from ruptured splenic aneurysm 
and cerebral edema with a normal liver graft function. Finally, some patients die 
or are retransplanted because of primary non function (PNF) or initial poor 
function (IPF) of the graft. Patients with PNF or IPF are often transplanted with 
carefully selected grafts of donors thought to be suitable for transplantation. 
Transplant procedures are often uneventful and nevertheless the grafts fail. IPF 
and PNF represent the entities of graft failure that are the least well understood. 
Some of these patients can only be kept alive with a new graft. The need for 
retransplantation and an observed decreased survival under such circumstances 
are serious sequelae of non-function and demand better understanding of risk 
factors possibly involved in its mechanisms.
In the following paragraphs, the current knowledge about primary non-function 
and initial poor function will be reviewed, with special focus on factors 
predicting early graft function.
Definition of early graft function
If one is to study graft function after liver transplantation, and results should be 
compared to the literature, this can only be done if endpoints are well defined. 
Unfortunately thus far, there is no consensus on the definition of primary non 
function or early graft dysfunction, not only in terms, but also even in the 
choice of parameters that define the condition. For example, many studies 
simply presume primary non function to be present in case a patient has to be 
retransplanted because of liver failure not due to rejection or technical failure 
within a certain time (range 2-90 days)20,22. In case of early graft dysfunction, 
the criteria broaden even further. Sometimes liver enzymes23,24 are used to 
define this condition, sometimes bile production25,26. In other cases liver function 
tests27 or protein synthesis28 are monitored. In many reports a combination of 
these test is proposed to qualify graft function20,23,29-31. It is easily understood that 
comparing results is difficult in these situations: choosing different 
parameters could identify different factors influencing graft failure.
Therefore, it is important to realize that the current review includes many 
Chapter 1
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studies not using individual liver graft parameters or graft function but also 
graft survival in the early postoperative phase as an endpoint.
 
Donor characteristics
Although donor selection has been a key issue since the start of liver 
transplantation programs, it is still unclear which criteria should be used for 
donor selection32-35. 
Consequently, based on clinical experience acceptance criteria for donors 
have been widened over the past years36-39. ABO matched, young adult, 
hemodynamically stable, healthy donors are generally accepted. Matching for 
blood group remains a prerequisite, despite the fact that ABO mismatch not 
necessarily leads to graft failure40. A positive cross match is also thought to be 
predictive of early graft loss41, however the review by Donaldson and Williams42 
clearly showed that this issue thus far is unresolved with regard to both early 
graft loss due to (hyper) acute and/or chronic rejection.
Older donors were accepted without apparent effect on outcome43. Inotropic 
upport is often necessary in donors and so far no maximum concentration has 
been identified. Numerous reports have shown that grafts from donors previously 
infected with hepatitis B or C can be transplanted in selected patients44-47 
Also polycystic livers48, livers from patients dying from carbon monoxide 
poisoning, septic donors49 and even grafts from deceased transplant recipients, 
have been used with success.
Not surprisingly, donor liver functions have been proposed to predict graft 
function. For example lidocaine clearance50, indocyanide green clearance51,52, clot-
ting factor concentrations and transaminase53 concentrations have been 
presented as determinants of early graft function. Grafts from donors that cleared 
lidocaine at low rates performed less well. However these enthusiastic initial 
reports on lidocaine clearance as predictor of early graft dysfunction were not 
supported by later studies50,54-56.
Another factor that appears to be associated with transplant function is duration 
of stay of the donor in the intensive care unit (ICU) and/or prolonged ventilation 
dependency. Grafts from donors that were in the ICU for more than 5 days 
showed a higher risk for primary non function20,32,34. Many mechanisms 
Introduction and outline of the thesis
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might explain this finding. For example, patients in the ICU are more often 
hemodynamically unstable, hormonal regulation is deranged, f luid and 
electrolyte balances are disturbed and many inflammatory cascades are 
upregulated. Especially plasma sodium > 155 mmol/L appears to be an important 
factor57,58, since grafts from donors with these high levels were associated with 
decreased graft survival. Fortunately, correction of hypernatrimia in the donor 
can overcome this problem59. Probably closely related to duration of ICU stay is 
the nutritional status of the donor, which is also thought to influence outcome. 
Experiments in rats have shown the negative effect of fasting on transplant 
success60-62. These studies were not confirmed by others63, nor were the results 
invariable reproducible in pigs64,65. More importantly, it is likely that not 
feeding itself is the pivotal issue but the depletion of glycogen in the liver as a 
source for ATP regeneration seems to be essential62,65,66,67. Some reports on
initial graft function in humans were able to link increased microscopic fat68 
up to 30% in graft or increased donor weight with graft dysfunction69,70. 
However, there are at least as many studies published that do not confirm 
these initial findings71. 
Lately donor gender72,73 and race74,75 have been raised as factors influencing graft 
survival. Female grafts in male recipients showed decreased graft survival as 
did race mismatched liver transplant procedures. However, these two factors are 
given entities and are difficult to balance in a situation of organ shortage. 
Furthermore the mechanisms of how gender differences in donor recipient 
combinations might work are difficult to understand.
Recently, brain death with all its pathophysiologic sequelae came to attention as 
possible cause for poor postoperative graft function76. This interesting issue 
needs to be pursued further, because it is evident from clinical experience that 
renal grafts from living donors perform better and have a longer survival 
compared to grafts from postmortem donors. So far, the importance of this 
finding however remains under debate since in a canine model, the importance 
of the relation between brain death and organ function could not be reproduced77.
Some studies have explored endotoxin78,79 and cytokine concentrations in 
donors80 and have tried to link elevated concentrations of these substances to 
reduced transplant success, but so far without definite confirmation. 
Chapter 1
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Recipient characteristics
In the search for useful predictors of graft function, not only donor characteristics 
have been studied. The focus has also been on recipient characteristics81. 
Especially since the recipient was soon recognized as a possible “hostile 
environment”82. Although this statement is mainly based on the fact that a 
recipient will immunologically respond to the new graft, the donor liver is 
implanted in a recipient with many other problems. These other problems are 
related to the primary diagnosis and stage of the disease leading to transplantation. 
Acute hepatic failure in patients needing a liver graft is one of the most important 
determinants of outcome after liver transplantation83. In chronic hepatic failure, 
the underlying disease might also influence early graft function. There are large 
differences in 6-month graft survival between groups of patients with different 
diseases leading to chronic liver failure2. So far, this effect is not completely 
understood. One reason why original disease might lead to differences in IPF is 
that serum cytokine concentrations differ in some diseases84-86. These differences 
might lead to differences in early graft function, since cytokines are supposed to 
play an essential role in ischemia and reperfusion syndromes87.
Another important issue in chronic liver failure, possible influencing the rate of 
graft dysfunction is the timing of the transplantation during the course of the 
disease. 88. For this purpose many scoring systems have been evaluated. 
For example the Child-Pugh score, the Mayo survival model for patients with 
primary biliary cirrhosis, the UNOS score and Shaw scoring system89 are used to 
identify patients that would benefit from transplantation in the near future. 
Early data from the UNOS registry reveal that the higher the score in some of 
these systems the fewer patients survive the procedure. In general most studies 
showed that high-risk patients (high scores in these systems) tend to do less 
well.  Import to note is that over the last decades the natural history of chronic 
liver disease has changed in such a way that patients live longer without being 
transplanted due to the improved non-surgical treatment modalities. Patients 
might not need a new liver or may need a new liver later in the course of their 
disease. This affects outcome, since older patients have a decreased patient and 
graft survival and often also have early graft dysfunction38. Timing is even more 
problematic since increased waiting time results in higher mortality on the wai-
ting list90. Renal function is another factor in the recipient determining early 
Introduction and outline of the thesis
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graft function, since patients with decreased kidney function show 
decreased patient and graft survival. Unfortunately, studies that relate kidney 
function to graft function or transplantation success have used different 
parameters to quantify or qualify renal impairment. Such as serum creatinin 
concentrations91, blood urea nitrogen92, creatinin clearance, hepatorenal 
syndrome93, or renal insufficiency20,94 were used in different studies.
Nutritional state has been investigated as a potential predictor of transplant 
success89,95,96. Malnourished patients represent a group at high risk for 
infection, graft failure and fatality. However, in patients on the waiting list for 
liver transplantation it is difficult to assess the nutritional state. Albumin is 
usually low because of the underlying liver disease and weight is influenced by 
the presence of ascites or muscle wasting. Other measurements, like deviation of 
measured from predicted resting energy expenditure or body cell mass, may be 
difficult to obtain. Moreover, a prospective study, in which improvement of 
nutritional state is shown to improve outcome, is not available. Recently 
anthropometrical measurements have been shown to be a possible parameter 
to use in such studies97,98. 
Also as in donors, race99,100 mismatch in gender75,101 appears to be related to graft 
function, since graft survival is lower in male recipients from female grafts.
Graft characteristics
It appears very attractive to be able to test a graft before implantation. In this 
way not only all donor variables are included, but also the effects of factors like 
donor conditioning, organ retrieval, type of preservation fluid, quality of 
perfusion102, duration of cold and warm ischemia times 103-105  and machine 
perfusion106,107 can be included. Thus far several approaches have been tried. 
Grafts biopsies have been tested for normal histology24,70,108 viability109, energy 
content110-112 and function113,114. These tests were initiated under the assumption 
that during cold ischemia changes in different cell types can be identified and 
therefore correlated to outcome. Nuclear magnetic resonance spectroscopy of the 
graft110 was used to quantify ATP content of the graft. If a graft is preserved, 
aerobic metabolism is interrupted and therefore ATP synthesis stops and thus 
ATP levels will drop. Absence of ATP or absence of ATP regeneration capacity 
Chapter 1
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might be associated with postoperative graft function111,115. Our group 
has shown that it is possible to isolate hepatocytes and that these cells can 
subsequently be studied for taurocholic acid uptake as a parameter for 
function113. Unfortunately, non of the mentioned approaches proved to be 
helpful in the clinical situation. An important issue might be that most studies 
focused on hepatocytes, while non parenchymal cells are considered increasingly 
important for adequate function of the liver116. 
Surgical characteristics
Also surgical factors have influence on graft function. Longer duration of
ischemia, whether cold or warm103-105, is a well-known factor that influences 
postoperative graft function in a negative way. However the physical distance to 
be bridged between donor and recipient center is a given entity determining for 
a large part the duration of the cold ischemic time. If for some reason livers have 
to be reduced or split cold ischemic time will consequently be prolonged. 
This is reflected in the sometimes-observed rise in transaminases and poor graft 
function after such extended procedures. Over the years the type of preservation 
fluid has proven to have influence on early graft function. The introduction of 
the University of Wisconsin solution made not only possible to preserve grafts 
for a longer time but also graft function improved after transplantation117,118 
The duration of warm ischemia is partly determined by technical difficulties that 
may be encountered during surgery, such as the need for vascular reconstructions. 
Also the way the operation is conducted is important. Procedures with careful 
and meticulous hemostasis with consequently reduced blood loss show a better 
postoperative graft function 119,120. 
Some studies have explored the influence of timing of portal and arterial 
revascularization121,122 on early graft function. Simultaneous release of the portal 
vein and the hepatic artery might be superior to sequential approaches. 
Some groups do flush the graft with different types of fluids, like Carolina rinse 
solution or albumin, just before recirculation. The preservation fluid together 
with possible toxic substances having accumulated in this fluid during storage 
is removed in this way and organ damage is reported to be less. 123-125. However, 
this policy has not been universally accepted in daily practice. 
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Finally, surgery itself might be an important factor determining postoperative 
graft function. It has been shown that various acute phase responses are triggered 
during operations126. These triggered systems range from cytokines to complement 
system and vascular active substances like nitric oxide. In this respect liver 
transplantation appears not to be different from other surgical procedures. 
However the exact role of these substances on early graft function remains to be 
assessed.  The gut is thought to play an important additional role in this cascade127. 
During the procedure, blood flow through the gut is compromised. This leads to 
translocation of bacteria or endotoxins from the intestines to the circulation and 
subsequently to activation of cytokines. 
Ischemia reperfusion effects
Ischemia/reperfusion (I/R) is currently the subject that is most studied in the 
setting of early graft function. Some excellent reviews have been written128-132. 
Four major effects explain most of the I/R injury, all of which become manifest 
on reperfusion. These are sinusoidal lining cell injury, white cell adhesion, platelet 
adhesion and increased coagulation. There is a definite role for free oxygen 
radicals128,133,134 and xanthine oxidase 135 by inducing cell injury to hepatocytes and 
other cell types. Cytokines136, like tumor necrosis factor α 137, interleukin-1 and 
interleukin-6 also play an important role. 138,195. Tumor necrosis factor α leads to 
procoagulant activation, reduction of protein C activity, membrane bound 
antigen activation and over-expression of adhesion molecules on 
endothelial cells and leucocytes. It also causes release of cytokines, free oxygen 
radicals and increased neutrophil aggregation and adherence.  TNF-α causes 
release of vasoactive substances like nitric oxide. Interleukin-1 initiates the 
secretion of other cytokines and activates endothelial cells. Interleukin-6 leads 
to induction of acute phase proteins and enhances immune function. In addition 
to inducing and amplifying a local inflammatory response, this cascade induces 
both necrosis and apoptosis of hepatocytes, either direct or through induction of 
nitric oxide expression by the hepatocytes. In animal experiments 140,141 the role 
of these cytokines has been extensively explored, but the exact role in human 
liver transplantation remains controversial and needs to be elucidated 142-155. 
Despite the possible relationship between increased cytokine concentrations 
Chapter 1
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and postoperative organ failure it has been shown that cytokine removal is not 
helpful156.
Other factors implicated in I/R injury128-130 range from Matrix Metallo proteases, 
calcium, phospholipase A2, eicosanoids to platelet activating factor, endothelin 
and adhesion molecules. All these substances initiate an inflammatory response 
with upregulation of adhesion molecules, neutrophil sequestration and priming 
of neutrophils and macrophages for increased cytotoxicity. 
Finally endotoxin should be mentioned, since it may also contribute to I/R 
injury. The presence of endotoxin has been shown during liver transplantation 
and has been linked to adverse outcome157-159. Since the liver plays a key role in 
clearance of endotoxin and is probably deficient before and definitely absent 
during the anhepatic phase of the transplantation, endotoxin could enhance 
ischemia reperfusion effects. Endotoxin can damage hepatocytes, render 
macrophages cytotoxic and induce release of biologically active mediators and 
free oxygen radicals 
Conclusion
This review shows that many factors can influence early graft function. 
Unfortunately most of them are still only partly understood and definitive proof 
of their influence and mechanisms of action are not always present. Several 
handicaps exist for adequate comparison of studies reported in the literature. 
Studies are often done in different species or in populations with a different 
composition (non homogeneous populations). The lack of consensus on the 
definition of early graft dysfunction is still a major issue.
Among the donor factors accepted as playing an important determining role in 
early graft function after liver transplantation are; duration of ICU stay, an 
increased serum sodium (above 150 mmol/L), and possibly brain death has in 
itself detrimental effects on graft function.
In liver transplantation clinicians are aware that also recipient factors play an 
important a role in the development of postoperative graft function. Factors 
proven to correlate significantly with early graft function are pretransplant 
kidney function and diagnosis and stage of disease.
Surgical factors like length of cold ischemia time, blood loss and probably rinsing 
Introduction and outline of the thesis
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are important as well. Finally, it is obvious that preservation-reperfusion injury 
also plays a key role in postoperative graft function. Despite increasing knowledge 
of the mechanisms at the cellular and molecular levels, more studies are needed 
before effective interventions can be implemented in human liver transplantation.
Outline of the thesis
The investigations, described in this thesis, approach the problem of initial liver 
graft function from various angles.
Chapter 2 investigates the incidence of early graft dysfunction in a homogeneous 
group of patients in our center. Since there is a lack of consensus on the criteria 
for early graft dysfunction we also studied whether two commonly used sets of 
criteria showed concordance. Finally, we analyzed whether any particular donor, 
recipient or transplantation related parameters could predict early graft function 
in a well-defined homogeneous patient cohort.
Chapter 3 and 4 focus on the analysis of a number of tests performed in materials 
obtained from the graft before implantation (biopsies, cells, slices) and their 
ability to predict graft function after transplantation. 
In chapter 3 the impact of the monoethylglycinexylide (MEGX) test in the donor 
is assessed. In addition, the results of a MEGX test performed in vitro in isolated 
liver slices are presented. 
In chapter 4 tests for hepatic transport function and metabolic tests are studied 
in isolated hepatocytes and liver slices of donor livers to determine whether they 
can predict early graft function.
In chapter 5 through 7 peroperative recipient variables are assessed in order to 
clarify their role in the clinical setting. These parameters (gastric mucosal pH, 
cytokines and endotoxin) were chosen because they are closely related to one an 
other and either animal or clinical experiments suggest they might play a role in 
early graft failure.
In chapter 5 the gastric mucosal pH as a measure of splanchnic perfusion of the 
recipient is investigated to determine whether it correlates with early graft 
function and clinical outcome.
In chapter 6 the role of endotoxin and cytokines like TNF-alpha and IL-1 and 6 is 
studied in relation to early graft function.
Chapter 1
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Finally, Chapter 7 investigates the effect on early graft function of selective 
decontamination of the digestive tract on endotoxemia, cytokine concentrations 
and early graft function.
The thesis is concluded by a summary and conclusions in chapter 8.
Introduction and outline of the thesis
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